\
&
Contact us
\
&
Contact us
This was 11 months ago
LocationOnline
ProgrammesERA4Health invites interested stakeholders to a webinar featuring Dr. Frank Hulstaert, Senior Researcher at the Belgian Health Care Knowledge Centre (KCE).
Dr. Frank Hulstaert, M.D., , will discuss “Pragmatic Comparative-Effectiveness Randomized Trials: Real-World Evidence for Better Health Decisions.” The session will provide valuable insights into how real-world evidence can enhance health decision-making. Additionally, it will serve as an excellent introduction of the upcoming first call for Investigator Initiated Clinical Studies under the ERA4Health Partnership, focusing on pragmatic comparative-effectiveness studies, in November 2024.
More information and registration on the ERA4Health website.
Background: The Partnership “Fostering a European Research Area for Health” (ERA4Health) aims at establishing a flexible and effective coordination between funding organisations in the European Research Area (ERA) for Health and Well-being. This Partnership brings the opportunity to increase European transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing European public health needs.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
